B. Riley Securities initiated coverage on MiNK Therapeutics with a new price target

11/9/21 7:57:17 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

B. Riley Securities initiated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $24.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$INKT

Date	Price Target	Rating	Analyst
1/24/2022	$24.00 → $10.00	Buy	B. Riley Securities
11/9/2021	$24.00	Buy	B. Riley Securities
11/9/2021	$26.00	Outperform	Robert W. Baird
11/9/2021		Outperform	William Blair
11/9/2021	$30.00	Outperform	Evercore ISI Group
11/9/2021	$26.00	Outperform	Baird